THE COVID-19 PANDEMIC’S IMPACT ON TREATMENT DECISION-MAKING FOR OLDER PATIENTS WITH KIDNEY DISEASE

Findings may provide insights for supporting shared decision-making through current and future pandemics.

Highlight
- A recent study examined how uncertainty surrounding the evolving COVID-19 pandemic influenced shared decision-making between clinicians, older patients with chronic kidney disease, and their care partners.

Washington, DC (June 7, 2022) — The COVID-19 pandemic disrupted medical care for many individuals, including older patients with advanced chronic kidney disease (CKD). A recent study published in CJASN examined how shared decision-making—the process by which clinicians, patients, and their care partners work together to make decisions about treatments and care—was influenced by the uncertainty surrounding the evolving pandemic.

For the study, Keren Ladin, PhD, MSc (Tufts University) and her colleagues interviewed 76 adults (39 older patients with advanced CKD, 17 care partners, and 20 clinicians) from Boston, Portland (Maine), San Diego, and Chicago from August–December 2020.

The team found that clinicians perceived greater vulnerability among older patients with CKD and they more readily encouraged home-based modalities during the COVID-19 pandemic, but their discussions of vulnerability, advanced care planning, and conservative management remained limited. Lack of discussions of COVID-19–related risks, fewer education options, and inconsistent discussions of advanced care planning and conservative management left patients with unaddressed concerns and the need to navigate the emerging COVID-19 guidance on their own.

Despite heightened uncertainty, patient preferences for treatment modality (such as dialysis) remained stable, and most perceived their chosen modality to be the safest. Importantly, clinicians reported burnout caused by the pandemic, increased time demands, and workforce limitations.
“To improve shared decision-making during the pandemic and its aftermath, clinicians should promote and encourage conversations with patients who want to talk about COVID-19, with an emphasis on safety and quality-of-life, including the risks posed to them by COVID-19 and the impact of COVID-19 on treatment options. These discussions should present all options, including conservative management, and incorporate advanced care planning,” said Dr. Ladin. “Also, clinician burnout must be addressed with adequate resources and appropriate training.”

Study authors include Thalia Porteny, PhD, MSc, Kristina M. Gonzales, Kate E. Aufort, Sarah Levine, John B. Wong, MD, Tamara Isakova, MD, Dena E. Rifkin, MD, Elisa J. Gordon, PhD, MPH, Ana Rossi MD, Gary Di Perna, MD, Susan Koch-Weser, ScD, Daniel E. Weiner, MD, MS, and Keren Ladin, PhD, MSc.

Disclosures: The study was funded by a Patient-Centered Outcomes Research Institute (PCORI) Award (CDR-2017C1-6297). There are no conflicts of interests to disclose. Dr. Isakova received consulting honorariums from Akebia Therapeutics, Inc., Kyowa Kirin Co., Ltd., LifeSci Capital, LLC. Dr. Weiner has received consulting honoraria from Akebia Therapeutics (paid to Dialysis Clinic, Inc.) and Cara Therapeutics.


The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

About ASN
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 132 countries. For more information, visit www.asn-online.org and follow us on Facebook, Twitter, LinkedIn, and Instagram.

###